Skip to main content

Meibomian Gland Dysfunction

7
Pipeline Programs
11
Companies
16
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
1
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Loteprednol/tobramycinPhase 41 trial
Active Trials
NCT01456780Completed60Est. Jun 2017
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
Loteprednol/tobramycinPhase 4
Azura Ophthalmics
Azura OphthalmicsIsrael - Tel Aviv
1 program
1
AZR-MD-001Phase 35 trials
Active Trials
NCT06329791Active Not Recruiting500Est. Nov 2025
NCT05548491Completed67Est. Oct 2023
NCT04391959Completed31Est. Jan 2021
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
AGN-195263 0.1%Phase 21 trial
Active Trials
NCT01633788Completed232Est. Feb 2015
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
AZR-MD-001 Low DosePhase 21 trial
Active Trials
NCT03652051Completed321Est. Oct 2022
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
AzasitePhase 2
MSD
MSDIreland - Ballydine
1 program
1
AzasitePhase 21 trial
Active Trials
NCT01797107Withdrawn0Est. Jul 2014
Alcon
AlconFORT WORTH, TX
4 programs
FID 114657N/A1 trial
Systane BalanceN/A1 trial
Systane iLux thermal pulsation treatmentN/A1 trial
Systane iLux® Dry Eye SystemN/A1 trial
Active Trials
NCT01079858Completed49
NCT01207752Completed69Est. Jul 2011
NCT05306561Unknown30Est. Dec 2023
+1 more trials
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Tear Restore MaskN/A1 trial
Active Trials
NCT04309799Unknown50Est. Feb 2023
Calico
CalicoLONG BEACH, CA
1 program
iLUX Treatment SystemN/A1 trial
Active Trials
NCT06278584CompletedEst. Feb 2022
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
senofilcon AN/A1 trial
Active Trials
NCT01819194Completed64Est. Aug 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthLoteprednol/tobramycin
Azura OphthalmicsAZR-MD-001
Azura OphthalmicsAZR-MD-001
Azura OphthalmicsAZR-MD-001
Azura OphthalmicsAZR-MD-001
Azura OphthalmicsAZR-MD-001
Syneos HealthAZR-MD-001 Low Dose
MSDAzasite
AbbVieAGN-195263 0.1%
AlconSystane iLux thermal pulsation treatment
Colorado TherapeuticsTear Restore Mask
CalicoiLUX Treatment System
AlconSystane iLux® Dry Eye System
Johnson & Johnsonsenofilcon A
AlconSystane Balance

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 1,830 patients across 16 trials

NCT01456780Bausch HealthLoteprednol/tobramycin

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

Start: Aug 2011Est. completion: Jun 201760 patients
Phase 4Completed

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Start: May 2024Est. completion: Nov 2025500 patients
Phase 3Active Not Recruiting

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Start: Jul 2020Est. completion: Jan 202132 patients
Phase 2/3Completed

Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)

Start: Nov 2022Est. completion: Oct 202367 patients
Phase 2Completed

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Start: Jul 2020Est. completion: Jan 202131 patients
Phase 2Completed

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Start: Oct 2019Est. completion: Dec 202026 patients
Phase 2Completed
NCT03652051Syneos HealthAZR-MD-001 Low Dose

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Start: Sep 2018Est. completion: Oct 2022321 patients
Phase 2Completed

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Start: Mar 2013Est. completion: Jul 20140
Phase 2Withdrawn
NCT01633788AbbVieAGN-195263 0.1%

A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Start: Aug 2012Est. completion: Feb 2015232 patients
Phase 2Completed
NCT05306561AlconSystane iLux thermal pulsation treatment

Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users

Start: Jan 2022Est. completion: Dec 202330 patients
N/AUnknown

The Effect of Warm Compress Therapy Using the TearRestore Eyelid Warming Mask on Meibomian Gland Function

Start: Nov 2020Est. completion: Feb 202350 patients
N/AUnknown
NCT06278584CalicoiLUX Treatment System

iLux Treatment for Meibomian Gland Dysfunction

Start: Oct 2020Est. completion: Feb 2022
N/ACompleted
NCT03956225AlconSystane iLux® Dry Eye System

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

Start: Jun 2019Est. completion: Oct 2020299 patients
N/ACompleted

Contact Lens Comfort Relative to Meibomian Gland Status

Start: Mar 2013Est. completion: Aug 201364 patients
N/ACompleted
NCT01207752AlconSystane Balance

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

Start: Sep 2010Est. completion: Jul 201169 patients
N/ACompleted

Evaluation of FID 114657 in Dry Eye Subjects

Start: Feb 201049 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.